Andreas Behren
Andreas Behren
Olivia Newton-John Cancer Research Institute
Verified email at onjcri.org.au - Homepage
Title
Cited by
Cited by
Year
Whole-genome landscapes of major melanoma subtypes
NK Hayward, JS Wilmott, N Waddell, PA Johansson, MA Field, K Nones, ...
Nature 545 (7653), 175-180, 2017
6772017
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
ML Burr, CE Sparbier, YC Chan, JC Williamson, K Woods, PA Beavis, ...
Nature 549 (7670), 101-105, 2017
3282017
Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations
SCH Tsao, J Weiss, C Hudson, C Christophi, J Cebon, A Behren, ...
Scientific reports 5 (1), 1-11, 2015
1482015
BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage
VJ Mar, SQ Wong, J Li, RA Scolyer, C McLean, AT Papenfuss, RW Tothill, ...
Clinical Cancer Research 19 (17), 4589-4598, 2013
1232013
Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma
A Jayachandran, M Anaka, P Prithviraj, C Hudson, SJ McKeown, PH Lo, ...
Oncotarget 5 (14), 5782, 2014
942014
Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells
M Rigau, S Ostrouska, TS Fulford, DN Johnson, K Woods, Z Ruan, ...
Science 367 (6478), 2020
932020
BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
EF Lee, TJ Harris, S Tran, M Evangelista, S Arulananda, T John, ...
Cell Death & Disease 10 (5), 342, 2019
792019
A gene signature predicting natural killer cell infiltration and improved survival in melanoma patients
J Cursons, F Souza-Fonseca-Guimaraes, M Foroutan, A Anderson, ...
Cancer immunology research 7 (7), 1162-1174, 2019
782019
Characterising the phenotypic evolution of circulating tumour cells during treatment
SCH Tsao, J Wang, Y Wang, A Behren, J Cebon, M Trau
Nature communications 9 (1), 1-10, 2018
542018
BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition
MC Andrews, A Behren, F Chionh, J Mariadason, LJ Vella, H Do, ...
J Clin Oncol 31 (35), e448-e451, 2013
512013
FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis.
BS Tan, M Anaka, S Deb, C Freyer, LM Ebert, AC Chueh, S Al-Obaidi, ...
Oncotarget 5 (1), 264, 2014
492014
Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma
H Halse, AJ Colebatch, P Petrone, MA Henderson, JK Mills, H Snow, ...
Scientific reports 8 (1), 1-14, 2018
482018
Flt3 ligand expands CD4+ FoxP3+ regulatory T cells in human subjects
O Klein, LM Ebert, D Zanker, K Woods, BS Tan, J Fucikova, A Behren, ...
European journal of immunology 43 (2), 533-539, 2013
482013
Papillomavirus E2 protein induces expression of the matrix metalloproteinase-9 via the extracellular signal-regulated kinase/activator protein-1 signaling pathway
A Behren, C Simon, RM Schwab, E Loetzsch, S Brodbeck, E Huber, ...
Cancer research 65 (24), 11613-11621, 2005
482005
Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma.
SQ Wong, A Behren, VJ Mar, K Woods, J Li, C Martin, KE Sheppard, ...
Oncotarget 6 (2), 1115-1127, 2015
432015
The Ludwig institute for cancer research Melbourne melanoma cell line panel
A Behren, M Anaka, PH Lo, LJ Vella, ID Davis, J Catimel, T Cardwell, ...
Pigment cell & melanoma research 26 (4), 597-600, 2013
412013
Phenotype-assisted transcriptome analysis identifies FOXM1 downstream from Ras–MKK3–p38 to regulate in vitro cellular invasion
A Behren, S Mühlen, GAA Sanhueza, C Schwager, PK Plinkert, PE Huber, ...
Oncogene 29 (10), 1519-1530, 2010
412010
PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation
CSA Tutuka, MC Andrews, JM Mariadason, P Ioannidis, C Hudson, ...
Molecular Cancer 16 (1), 112, 2017
362017
Altered Expression and Splicing of ESRP1 in Malignant Melanoma Correlates with Epithelial–Mesenchymal Status and Tumor-Associated Immune Cytolytic Activity
J Yao, OL Caballero, Y Huang, C Lin, D Rimoldi, A Behren, JS Cebon, ...
Cancer immunology research 4 (6), 552-561, 2016
342016
Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors
M Anaka, C Hudson, PH Lo, H Do, OL Caballero, ID Davis, A Dobrovic, ...
BMC medical genomics 6 (1), 1-13, 2013
342013
The system can't perform the operation now. Try again later.
Articles 1–20